Patents Assigned to Mect Corporation
-
Patent number: 5763413Abstract: A Lewis-associated compound, represented by general formula (I), a process for producing the same, and an anti-inflammatory, wherein R.sup.1 and R.sup.3 represent each hydrogen, m SO.sub.3 H or CH.sub.2 COOH; R.sup.2 represents hydrogen, SO.sub.3 H, CH.sub.2 COOH or N-acetyl-neutraminic acid residue; R.sup.4 represents hydrogen; R.sup.5 represents O-lower alkyl, O-lower alkenyl, O-ceramide residue, O-mannose residue, O-galactose residue or O-lactose residue; R.sup.6 represents acetylamine; and R.sup.7 and R.sup.8 represent each hydrogen.Type: GrantFiled: August 30, 1995Date of Patent: June 9, 1998Assignee: MECT CorporationInventors: Masaaki Numata, Shigeki Nunomura, Shuji Fujita, Masami Iida, Akira Endo, Takayuki Ishii, Tomoya Ogawa, Mamoru Sugimoto, Ryoichi Osawa, Masamichi Fujita
-
Patent number: 5763420Abstract: An anti-inflammatory drug comprising as the effective component at least one compound selected from the group consisting of colominic acid, partial hydrolysis products of colominic acid and pharmaceutically acceptable salts, thereof. The drug is used as a drug for renal diseases, a drug for hepatitis, an immunomodulator and a drug for inhibiting the chemotaxis of neutrophil.Type: GrantFiled: May 25, 1995Date of Patent: June 9, 1998Assignee: MECT CorporationInventors: Ryoichi Osawa, Isao Suda, Masaaki Numata, Mamoru Sugimoto, Kenkichi Tomita, Nobuyuki Kibushi, Takayuki Ishii, Naokazu Sugiyama, Makiko Kasano, Tae Yasunaga, Makoto Tanaka, Tomoya Ogawa, Mariko Ishii
-
Patent number: 5668115Abstract: An anti-inflammatory drug comprising as the effective component at least one compound selected from the group consisting of colominic acid, partial hydrolysis products of colominic acid and pharmaceutically acceptable salts thereof. The drug is used as a drug for renal diseases, a drug for hepatitis, an immunomodulator and a drug for inhibiting the chemotaxis of neutrophil.Type: GrantFiled: May 25, 1995Date of Patent: September 16, 1997Assignee: MECT CorporationInventors: Ryoichi Osawa, Isao Suda, Masaaki Numata, Mamoru Sugimoto, Kenkichi Tomita, Nobuyuki Kibushi, Takayuki Ishii, Naokazu Sugiyama, Makiko Kasano, Tae Yasunaga, Makoto Tanaka, Tomoya Ogawa, Mariko Ishii
-
Patent number: 5611445Abstract: A lid for a container, which is easy for separated disposal. The lid has a main body portion (1a) and a projected portion (1b) integrally formed at the substantially central portion of the upper surface (1a1) of the main body portion (1a), whereby the lid (1) for the container covers an opening portion of a bottle (container) (2) and a seal plug for blocking this opening portion.Type: GrantFiled: August 4, 1995Date of Patent: March 18, 1997Assignee: Mect CorporationInventors: Takashi Kano, Seizo Rai
-
Patent number: 5516764Abstract: An anti-inflammatory drug comprising as the effective component at least one compound selected from the group consisting of colominic acid, partial hydrolysis products of colominic acid and pharmaceutically acceptable salts thereof. The drug is used as a drug for renal diseases, a drug for hepatitis, an immunomodulator and a drug for inhibiting the chemotaxis of neutrophil.Type: GrantFiled: March 28, 1994Date of Patent: May 14, 1996Assignee: Mect CorporationInventors: Ryoichi Osawa, Isao Suda, Masaaki Numata, Mamoru Sugimoto, Kenkichi Tomita, Nobuyuki Kibushi, Takayuki Ishii, Naokazu Sugiyama, Makiko Kasano, Tae Yasunaga, Makoto Tanaka, Tomoya Ogawa, Mariko Ishii
-
Patent number: 5470962Abstract: An oligosialyl-1,2-dialkyl-sn-glycerol represented by the following formula (I): ##STR1## wherein each R.sup.1 independently represents a group selected from the group consisting of a hydrogen atom and alkali metal atoms, each R.sup.2 independently represents an alkyl group having 14 to 18 carbon atoms, Ac represents an acetyl group, and n represents an integer of from 0 to 20, and synthetic intermediates for their preparation useful as an immuno-stimulating agent, an antitumor agent, and a diagnostic and therapeutic agent for cancers.Type: GrantFiled: September 7, 1993Date of Patent: November 28, 1995Assignees: Rikagaku Kenkyusho, Mect CorporationInventors: Tomoya Ogawa, Shigeki Nunomura, Mamoru Sugimoto
-
Patent number: 5393742Abstract: A preparation is useful for treating renal disease, such as nephritis and especially nephrosis (nephrotic syndrome), which comprises an effective amount of N-acetylneuraminic acid shown by the formula ##STR1## wherein, when n is 1, Z represents hydrogens, lithium, potassium, sodium, ammonium or organic ammonium, and when n is 2, Z represents calcium, barium or magnesium, and a pharmacologically acceptable carrier.Type: GrantFiled: August 19, 1993Date of Patent: February 28, 1995Assignee: MECT CorporationInventors: Takayuki Ishii, Makiko Kasano, Tae Yasunaga, Mariko Ishii, Mamoru Sugimoto, Kenkichi Tomita, Takeshi Miyata, Makoto Tanaka
-
Patent number: 5264567Abstract: GM.sub.3 analogous compound (I) below: ##STR1## wherein one of R.sup.2 and R.sup.3 represents a neuramic acid group represented by general formula (V): ##STR2## R.sup.5 represents ##STR3## or hydrogen; R.sup.Type: GrantFiled: February 5, 1993Date of Patent: November 23, 1993Assignee: Mect CorporationInventors: Masaaki Numata, Mamoru Sugimoto, Shuji Fujita, Masanori Kobayashiu, Kenkichi Tomita, Makoto Tanaka, Tomoya Ogawa
-
Patent number: 5231177Abstract: Sodium N-acetylneuraminate trihydrate herein provided is represented by the following formula: ##STR1## The sodium N-acetylneuraminate trihydrate can be prepared, for instance, according to a method which comprises the steps of: dissolving sodium N-acetylneuraminate in water or in a mixture of water and an organic solvent; allowing the resulting solution to stand; precipitating and separating the resulting crystals of sodium N-acetylneuraminate.trihydrate; and then drying the separated crystals. The sodium N-acetylneuraminate trihydrate has very low hygroscopicity and hence can be handled without any difficulty in the form of powder.Type: GrantFiled: March 5, 1990Date of Patent: July 27, 1993Assignee: Mect CorporationInventors: Kinichi Saito, Hideo Mizu, Naokazu Sugiyama, Shikoh Minagawa, Motoaki Goto, Kenji Abiko
-
Patent number: 5217961Abstract: The present invention provides condensed quinoline compounds represented by the following general formula (I): ##STR1## in which Z is NH, X is hydrogen, L is lower alkoxy, M is NHQ, Q is --SO.sub.2 CH.sub.3, Y is --NHR, and R is: ##STR2## These compounds are effective for inhibiting KB-cell growth and prolongation of the life span of mice implanted with tumor P-388.Type: GrantFiled: September 16, 1991Date of Patent: June 8, 1993Assignee: Mect CorporationInventors: Masatoshi Yamato, Kuniko Hashigaki
-
Patent number: 5177062Abstract: A preparation for treating immune complex diseases which comprises injection containing the following compound: ##STR1## wherein when n is 1, Z represents a hydrogen, lithium, potassium, sodium, ammonium or organic ammonium, and when n is 2, Z represents calcium, barium or magnesium, as an active ingredient and pharmacologically acceptable carrier. The preparation of the present invention may be used in any administration method such as hypodermic, intramuscular and intravenous.Type: GrantFiled: March 20, 1989Date of Patent: January 5, 1993Assignee: MECT CorporationInventors: Takeshi Miyata, Kazuo Takahama, Hirofumi Kai, Takayuki Ishii, Keiji Komatsu
-
Patent number: 5173420Abstract: A monoclonal antibody A exhibits specificity to the sialic acid glycolipid containing the epitope NeuAc.alpha.2.fwdarw.9NeuAc terminal. A monoclonal antibody B exhibits specificity to the sialic acid glycolipid containing the epitope NeuAc.alpha.2.fwdarw.6Gal.beta. terminal. A monoclonal antibody C exhibits specificity to the sialic acid glycolipid containing at least one epitope selected from the group of NeuAc.alpha.2.fwdarw.9NeuAc terminal, NeuAc.alpha.2.fwdarw.6Gal.beta. terminal and NeuAc.alpha.2.fwdarw.1Cer. Hybridomas are prepared which produce antibodies A, B and C. A process for producing the hybridomas is disclosed including the step of fusing a myeloma cell and a B cell (lymphocyte) produced by the immunization of animal using as an antigen, the sialic acid glycolipid containing at least one epitope of the group NeuAc.alpha.2.fwdarw.9NeuAc terminal, NeuAc.alpha.2.fwdarw.6Gal.beta. terminal and NeuAc.alpha.2.fwdarw.1Cer.Type: GrantFiled: February 15, 1989Date of Patent: December 22, 1992Assignee: MECT CorporationInventors: Reiji Kannagi, Yoshiko Kirihata, Tomoya Ogawa, Masaaki Numata, Mamoru Sugimoto
-
Patent number: 5158886Abstract: A hybridoma producing a monoclonal antibody specific for free N-acetylneuraminic acid or beta glycoconjugates thereof, is herein disclosed. The hybridoma can be generated by fusing (i) B cells of lymphocytes obtained by immunizing an animal with an N-acetylneuraminic acid or a beta-glycoconjugate thereof, and (ii) myeloma cells.Type: GrantFiled: November 8, 1988Date of Patent: October 27, 1992Assignee: MECT CorporationInventors: Atsushi Kawamura, Isao Suda, Kinji Takada, Masayoshi Ito, Yoshiyasu Shitori
-
Patent number: 5141864Abstract: A hybridoma capable of producing a monoclonal antibody specific to a sialic acid containing glycolipid carrying N-acetylneuraminic acid residue having alpha 2.fwdarw.3 linkage is herein disclosed. The hybridoma can be generated by fusing (i) B cells or lymphocytes obtained by immunizing an animal with a sialic acid containing glycolipid carrying N-acetylneuraminic acid residue having alpha 2.fwdarw.3 linkage and (ii) myeloma cells. The monoclonal antibody produced by the hybridoma can be used for purifying gangliosides, for treating patients suffering from melanoma and for diagnosing sera.Type: GrantFiled: November 14, 1988Date of Patent: August 25, 1992Assignee: Mect CorporationInventors: Yoshitaka Nagai, Hideki Yamamoto, Kinji Takada, Ito, Yoshiyasu Shitori
-
Patent number: 5142028Abstract: A monoclonal antibody specifically recognizes an epitope or an antigenic determinant represented by the following formula and specifically reacts therewith: ##STR1## The monoclonal antibody can be obtained by cultivating hybridoma cells which can be generated by a method comprising cell-fusing (A) B cells or lymphocytes obtained by immunizing an animal with a substance involving the epitope or the antigenic determinant represented by the foregoing formula and (B) myeloma cells. The monoclonal antibody shows high specificity to ganglioside GQ.sub.1b and ganglioside GT.sub.1a having a specific epitope and thus can detect the epitope in high sensitivity. Therefore, the antibody can be used for the elucidation of sugar chain's roles in cell functions and for studying the development of animals. Moreover, the monoclonal antibody would have various clinical applications.Type: GrantFiled: July 10, 1989Date of Patent: August 25, 1992Assignee: Mect CorporationInventors: Yoshitaka Nagai, Hideki Yamamoto, Kinji Takada, Masayoshi Ito
-
Patent number: 5128345Abstract: Novel indoloquinoline compounds of formula (I), benzo(b)acridines of formula (II) and benzo(c)acridines of formula (III) have carcinostatic activities. The compounds, processes for preparing the compounds via nucleophilic aromatic substitution, and carcinostatic compositions containing the same are disclosed.Type: GrantFiled: March 3, 1989Date of Patent: July 7, 1992Assignee: Mect CorporationInventor: Masatoshi Yamato
-
Patent number: 5126330Abstract: The present invention relates to a sodium salt of sialosyl cholesterol. The present compound has an excellent high water solubility, and therefore the compound is very useful as a medicine to be used for treating various diseases derived from lesions of peripheral or central nerves.Type: GrantFiled: February 1, 1991Date of Patent: June 30, 1992Assignee: Mect CorporationInventors: Haruo Ogura, Kimio Furuhata, Shingo Sato, Masayoshi Ito, Yoshiyasu Shitori, Yoshitaka Nagai
-
Patent number: 5101026Abstract: The present invention relates to ganglioside related compounds having, for example, the following formula: ##STR1## where R.sub.1 represents H or COCH.sub.3 (hereinafter abbreviated to "AC"); R.sub.2 represents H or CH.sub.3 ; and R.sub.3 represents --OH, ##STR2## These ganglioside related compounds are useful as membrane receptors, tumor markers, cell growth controlling substances, etc., and useful for immunotherapy for cancer, etc.Type: GrantFiled: August 6, 1987Date of Patent: March 31, 1992Assignee: MECT CorporationInventors: Tomoya Ogawa, Mamoru Sugimoto, Masaaki Numata, Masayoshi Ito, Yoshiyasu Shitori, Shigeki Nunomura
-
Patent number: 5077397Abstract: Sialic acid derivative with active ester groups expressed with the formula [I] ##STR1## Where R.sup.1 denotes hydrogen or an acetyl group, R.sup.2 denotes hydrogen or a lower alkyl group, R.sup.3 denotes C.sub.2 H.sub.4, C.sub.3 H.sub.6 or C.sub.2 H.sub.2, R.sup.4 denotes an hydroxyl group, the residue left after removing hydrogen from the alcohol portion of the active ester or alkyloxycarbonyloxy group, AC denotes an acetyl group, Ph denotes an phenyl group, and X denotes oxygen or sulfur. This sialic acid derivative has high reactivity because it has active ester groups in the molecules and can be used as a raw material or intermediate for synthesis of various sialic acid derivatives.Type: GrantFiled: November 27, 1989Date of Patent: December 31, 1991Assignee: MECT CorporationInventors: Shoji Yoshimura, Makoto Tanaka
-
Patent number: RE34091Abstract: A sialic acid derivative having an active carbonyl group represented by the formula [I]: ##STR1## wherein R.sup.1 represents hydrogen or acetyl group; R.sup.2 represents hydrogen, a metal or a lower alkyl group; R.sup.3 represents hydrogen, hydroxyl gorup, or a residue removed hydrogen from an alcohol portion of an active ester; Ac represents acetyl group; and n is 1 to 20, respectively. This sialic acid derivative [I] can be utilized as a starting material for various complex having a sialic acid in the molecule since it has an active carbonyl group in the molecules so that it shows high reactivity.Type: GrantFiled: October 21, 1991Date of Patent: October 6, 1992Assignee: MECT CorporationInventors: Shoji Yoshimura, Shohei Shibayama, Masaaki Numata, Masayoshi Ito, Yoshiyasu Shitori, Tomoya Ogawa